About ZetaGen
ZetaGen is a company based in Syracuse (United States) founded in 2017. ZetaGen has raised $33.26 million across 7 funding rounds from investors including New York State, National Cancer Institute and Consolidated Investment Group. ZetaGen offers products and services including ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®. ZetaGen operates in a competitive market with competitors including Horizon Therapeutics, Osteal Therapeutics, Angitia, Histogenics and Osiris, among others.
- Headquarter Syracuse, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Zetagen Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$33.26 M (USD)
in 7 rounds
-
Latest Funding Round
$12.91 M (USD), Series B
Oct 31, 2025
-
Investors
New York State
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ZetaGen
ZetaGen offers a comprehensive portfolio of products and services, including ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®.
Therapy to suspend cancer and regenerate bone in patients.
Targets primary cancers with potential to minimize side effects.
Treats metastatic breast cancer to reduce tumor burden.
Aids in bone regeneration for cancer-related lesions.
People of ZetaGen
Unlock access to complete
Unlock access to complete
Funding Insights of ZetaGen
ZetaGen has successfully raised a total of $33.26M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $12.91 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $12.9M
-
First Round
First Round
(26 Dec 2018)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - ZetaGen | Valuation |
investors |
|
| Jan, 2025 | Amount | Series B - ZetaGen | Valuation |
investors |
|
| Aug, 2023 | Amount | Series B - ZetaGen | Valuation | New York State , Consolidated Investment Group |
|
Investors in ZetaGen
ZetaGen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include New York State, National Cancer Institute and Consolidated Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Provides the information about government agencies in New York
|
Founded Year | Domain | Location | |
|
Cancer research is conducted and supported by the institute.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ZetaGen
Financial Statements - ZetaGen
Zetagen Comparisons
Competitors of ZetaGen
ZetaGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Osteal Therapeutics, Angitia, Histogenics and Osiris, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| domain | founded_year | HQ Location |
Drugs for muscle, bone, and joint diseases are developed.
|
|
| domain | founded_year | HQ Location |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Stem cell-based regenerative medicines are developed and marketed.
|
Latest news on Zetagen
Frequently Asked Questions about ZetaGen
ZetaGen was founded in 2017 and raised its 1st funding round 1 year after it was founded.
ZetaGen is headquartered in Syracuse, United States. It is registered at Syracuse, New York, United States.
ZetaGen is a funded company, having raised a total of $33.26M across 7 funding rounds to date. The company's 1st funding round was a Series B of $9.79M, raised on Dec 26, 2018.
ZetaGen was founded in 2017 and is based in Syracuse, United States. Small molecule-based therapeutics are developed by the company for bone regeneration, targeting injuries, procedures, and diseases. A molecular pathway is activated by these drugs, while osteoclast activity is down-regulated to reduce bone destruction. Operations focus on the biotechnology sector, with emphasis on orthopedic applications.
ZetaGen's top competitors include Horizon Therapeutics, Angitia and Osiris.
ZetaGen offers ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®.
ZetaGen has 3 investors. Key investors include New York State, National Cancer Institute, and Consolidated Investment Group.